Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of danicopan added to C5 inhibitor therapy in adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis
MOH_2022-04-20_010745Phase 3Not yet recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing danicopan + C5 inhibitor with placebo + C5 inhibitor (2 arms). Planned start Jan 2022; status: not yet recruiting.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on MOH_2022-04-20_010745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-20_010745.